Croda International Plc confirmed that following receipt of unconditional approval from the South Korean regulatory authorities, it has now completed the acquisition of Solus Biotech.

Croda announced on February 6 it agreed to acquire Solus Biotech, a leader in “premium, biotechnology-derived beauty actives” from Solus Advanced Materials for £232 million.

Croda is a Snaith, East Yorkshire-based FTSE 100 speciality chemicals giant.

Solus Biotech generated £28 million of sales in 2022. It employs 95 people in South Korea at its R&D centre in Bundag near Seoul and its production centre in Iksan.